FDA Inspection 1229211 — Homeocare Laboratories, Inc.

Homeocare Laboratories, Inc. — FEI 3008420443

The FDA completed an inspection of Homeocare Laboratories, Inc. on March 20, 2024 in Yonkers, NY. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 12 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
March 20, 2024
Fiscal Year
2024
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Yonkers, NY (United States)

Citations

IDCFRDescription
116221 CFR 211.28(a)Protective Apparel Not Worn
117721 CFR 211.63Equipment Design, Size and Location
121321 CFR 211.67(a)Cleaning / Sanitizing / Maintenance
122021 CFR 211.67(b)(3)Cleaning SOPs/instructions
136121 CFR 211.100(a)Absence of Written Procedures
184421 CFR 211.84(d)(2)Establish reliability of supplier's C of A
189021 CFR 211.165(e)Test methods
200921 CFR 211.188Prepared for each batch, include complete information
220521 CFR 211.186(b)(9)Manufacturing Instructions and Specifications
355921 CFR 211.56(a)Sanitation--buildings not clean, free of infestation
360321 CFR 211.160(b)Scientifically sound laboratory controls
457621 CFR 211.192No written record of investigation